UNSPSC 51384628: Mofebutazone sodium

This classification denotes a nonsteroidal antiinflammatory drug C13H15N2O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73X92I1U1W, chemically known as 3,5-pyrazolidinedione, 4-butyl-1-phenyl-, sodium salt (1:1), but more generally known as mofebutazone sodium, which bears US NIH Compound Identifier 16639. European Medicines Agency schedules Mofebutazone sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03313MIG.

Most nations, for tariff and trade purposes, schedule mofebutazone sodium under HS 29331990 and SITC 51571. As of Q4 2014, MOFEBUTAZONE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CCCC[C-]1C(=O)[NH]N(C1=O)C2CCCCC2.[NA+].

UNSPSC 51384628 Mofebutazone sodium is a Commodity-level code that in recent state and local activity does not map cleanly to the pharmaceutical products state and local governments are actually purchasing. The three recent opportunities tagged under this code reflect solicitations for naloxone and drug-deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription programs—none of which center on mofebutazone sodium as a discrete product line. The issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and other participating jurisdictions). The mismatch between the code's nominal scope and the actual procurement activity suggests either tagging inconsistency on the procurement platform or that mofebutazone sodium procurement through state and local channels is sufficiently rare that recent activity is categorized more broadly under generic pharmaceutical sourcing.

The geographic footprint evident in recent postings spans Florida, Texas, Minnesota, and Oregon, with activity concentrated in cooperative purchasing vehicles and state health agency procurement. Representative opportunities include Seminole County's IFB for naloxone and drug-deactivation systems (IFB60459723LAS, due July 26, 2023, seeking 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries), Minnesota's MMCAP RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026, with awards effective July 1, 2026 and a two-year initial term), and Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026). The code shows little activity directly relevant to mofebutazone sodium procurement; business development pursuit under this code should focus on broader pharmaceutical supply contracting through state health agencies and cooperative purchasing consortia rather than mofebutazone as a standalone commodity.